DOI: 10.6084/m9.figshare.26325145.v1
title: Supplementary data: Serious treatment-emergent adverse events in chronic low back pain patientstreated with buprenorphine or oral opioids: a retrospective commercial claims analysis

description: <b>These are peer-reviewed supplementary materials for the article '</b><b>Serious treatment-emergent adverse events in chronic low back pain patients </b><b>treated with buprenorphine or oral opioids: a retrospective commercial claims analysis' published in the</b><b> </b><b><i>Journal of Comparative Effectiveness Research</i></b><b>.</b><b>Table S1</b><b>:</b> ICD-10-CM codes related to low back pain<b>Table S2:</b> The relevant NDC codes related to CIII buprenorphine (Belbuca® and buprenorphine patch)<b>Table S3:</b> The list of ICD-10-CM codes related to relevant TEAEs<b>Table S4: </b>Demographic characteristics of non-matched patients (Primary Analysis: CIII Buprenorphine vs. CII Opioids)<b>Table S5:</b> Clinical characteristics of non-matched patients (Primary Analysis: CIII Buprenorphine vs. CII Opioids)<b>Table S6: </b>Demographic characteristics of non-matched patients (Sub-Analysis #1: Buprenorphine Buccal Film vs. CII Opioids)<b>Table S7:</b> Clinical characteristics of non-matched patients (Sub-Analysis #1: Buprenorphine Buccal Film vs. CII Opioids)<b>Table S8: </b>Demographic characteristics of non-matched patients (Sub-Analysis #2: Buprenorphine Buccal Film vs. Buprenorphine Patch)<b>Table S9:</b> Clinical characteristics of non-matched patients (Sub-Analysis #2: Buprenorphine Buccal Film vs. Buprenorphine Patch)<b>Table S10: </b>Demographic characteristics of matched patients (Primary Analysis: CIII Buprenorphine vs. CII Opioids)<b>Table S11:</b> Clinical characteristics of matched patients (Primary Analysis: CIII Buprenorphine vs. CII Opioids)<b>Table S12: </b>Demographic characteristics of matched patients (Sub-Analysis #1: Buprenorphine Buccal Film vs. CII Opioids)<b>Table S13: </b>Clinical characteristics of matched patients (Sub-Analysis #1: Buprenorphine Buccal Film vs. CII Opioids)<b>Table S14:</b> Demographic characteristics of matched patients (Sub-Analysis #2: Buprenorphine Buccal Film vs. Buprenorphine Patch)<b>Table S15: </b>Clinical characteristics of matched patients (Sub-Analysis #2: Buprenorphine Buccal Film vs. Buprenorphine Patch)<b>Aim: </b>Explore the safety of Belbuca (buprenorphine buccal film), buprenorphine transdermal patches and oral opioids for chronic low back pain (cLBP) treatment. <b>Methods: </b>The retrospective analysis of the MarketScan Commercial database (2018–2021) included treatment-naive cLBP adults. The first date of buprenorphine (Belbuca and transdermal patch) or opioid prescription was index date. Cohorts were defined based on the index medication. Observation included a 6-month pre-index period, while postindex lasted until the end of continuous insurance coverage. There were 44 relevant treatment-emergent adverse events (TEAEs) identified in the literature. Incidence rate ratio (IRR) and incidence rate difference (IRD) were used to compare serious TEAE rates (in 1000 person-years) between cohorts. Propensity-score matching minimized the selection bias. <b>Results:</b> Buprenorphine had lower rates of 15 serious TEAEs than oral opioids (all p ≤ 0.037), while higher rates only for serious dizziness (IRR 2.44, p = 0.011; driven by Belbuca), opioid abuse/dependence (IRR 3.13, p = 0.004; driven by patches) and cholecystitis (IRD 20.25, p = 0.044; an outlier). Additionally, a comparison between Belbuca and oral opioids showed lower rates of 13 serious TEAEs (all p ≤ 0.024) and a higher serious dizziness rate (IRR 3.17, p = 0.024). Although the rates of serious opioid abuse/dependence were similar (24.60 vs 26.93, p = 0.921), all Belbuca patients and none of the opioid patients had a positive history of these events. Belbuca also had lower rates of five serious TEAEs than transdermal patches (all p ≤ 0.018), including a serious opioid abuse/dependence (IRR 0.04, p &lt; 0.001), but higher rates of serious cholecystitis (IRD 52.17, p = 0.035; an outlier) and suicidal ideation (IRD 156.50, p &lt; 0.001; an outlier). <b>Conclusion: </b>Buprenorphine had a better safety profile than oral opioids in cLBP treatment. Belbuca showed a more favorable TEAE profile than buprenorphine transdermal patches and oral opioids.